Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Authors: Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, M. Roumiguié, Laurence E. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Haojie Li, Kijoeng Nam, Ekta Kapadia, Tara L. Frenkl, Ronald de Wit - The Lancet 2021 cited by 533